QGEN

49.3000.66%
RL

Ross L. Levine

Chair of the Scientific Advisory Board

Dr. Ross L. Levine M.D., is Director of American Association For Cancer Research. Dr. Ross L. Levine is Member of Scientific Advisory Board at Mission Bio Inc. since July 2021. He serves as Scientific Advisor at Scorpion Therapeutics, Inc. He served as a Member of Scientific Advisory Board at MANA Therapeutics, Inc., until March 2023. He serves as Chair of the Scientific Advisory Board at QIAGEN N.V. since 2021. He serves as Member of Scientific Advisory Board of Kurome Therapeutics, Inc. He is a Professor of Medicine at Weill Cornell Medical College. He is an Associate Attending Physician at Memorial Sloan-Kettering Cancer Center in the Human Oncology and Pathogenesis Program and Leukemia Service. He is the Founder & Member of Scientific Advisory Board of Auron Therapeutics, Inc. He serves as an Associate Editor of Haematologica. He leads a research lab investigating genetics and targeted therapies in myeloid malignancies and is interested in application of next-generation sequencing technology in the practice of medicine in hematologic cancers. He is a physicianscientist focused on researching and treating blood and bone marrow cancers as the Laurence Joseph Dineen Chair in Leukemia Research, the Director of the Center for Hematologic Malignancies and an Attending Physician at Memorial Sloan Kettering Cancer Center. He has been involved in the discovery and characterization of disease alleles in MPN and AML patients, including the identification of JAK2 and MPL mutations in MPN patients. He has Clinical Expertise in Leukemias, Myeloproliferative Neoplasms. He serves on the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society. Dr. Levine serves on the Editorial Board of Blood at Haematologica and Clinical Cancer Research and is a Member of the International Working Group for Myelofibrosis. He serves as Member of Scientific Advisory Board at Locust Walk Acquisition Corp. He serves as a Member of Scientific Advisory Board at IsoPlexis Corp. He serves as a Member of Scientific Advisory Board at QuanDx Inc. He served as Member of Scientific Advisory Board Zentalis Pharmaceuticals, Inc until October 2025. He has been Member of Scientific Advisory Board at C4 Therapeutics, Inc. since July 27, 2017. He had been an Independent Member of the Supervisory Board at Qiagen NV since 2016 until January 23, 2026. He serves as an Independent Director of Medicus Sciences Acquisition Corp., since February 12, 2021. He served as a Member of Scientific Advisory Board at Loxo Oncology, Inc. since October 3, 2013. He serves as Member of Scientific Advisory Board at Bakx Therapeutics Inc. He serves as Director of Ajax Therapeutics, Inc. He served as a Member of Scientific Advisory Board at CTI BioPharma Corp. from October 14, 2013 to January 21, 2017. He earned a Young Investigator Award from the American Society of Clinical Oncology, a Fellow Scholar Award from the American Society of Hematology and a Clinical Scientist Development Award from the Doris Duke Charitable Foundation. He is a Scholar of the Leukemia and Lymphoma Society. He trained in internal medicine at Massachusetts General Hospital and Fellowships from Dana-Farber Cancer Institute; Brigham and Women’s Hospital/Harvard Medical School. He has Board Certifications in Internal Medicine; Hematology and Medical Oncology. He has a MD from Johns Hopkins School of Medicine and his A.B. degree from Harvard College.

Positions